Agrawal Alok Chandra, Sakale Harshal, Garg Ankit Kumar, Inamdar Anupam
Department of Orthopaedics, All India Institute of Medical Sciences, Raipur, Chhatisgarh, India.
J Orthop Case Rep. 2023 Apr;13(4):57-61. doi: 10.13107/jocr.2023.v13.i04.3616.
The prevalence of avascular necrosis (AVN) of the femoral head in sickle cell anemia is 50% whereas untreated cases lead to total hip replacement. The recent development in cellular therapy paves the way to utilize autologous adult live-cultured osteoblasts (AALCO) in the management of AVN of the femoral head secondary to sickle cell anemia.
We performed AALCO implantation in sickle cell anemia cases with AVN of the femoral head and were followed up for 6 months with the regular recording of visual analog score and modified Harris Hip Score.
AALCO implantation for the management of AVN of the femoral head due to sickle cell anemia appears to be the biological management of choice as it results in pain reduction and improvement in function.
镰状细胞贫血患者股骨头缺血性坏死(AVN)的患病率为50%,而未经治疗的病例会导致全髋关节置换。细胞治疗的最新进展为利用自体成人活培养成骨细胞(AALCO)治疗镰状细胞贫血继发的股骨头缺血性坏死铺平了道路。
我们对患有股骨头缺血性坏死的镰状细胞贫血病例进行了AALCO植入,并进行了6个月的随访,定期记录视觉模拟评分和改良Harris髋关节评分。
AALCO植入治疗镰状细胞贫血所致股骨头缺血性坏死似乎是一种生物学上的首选治疗方法,因为它能减轻疼痛并改善功能。